Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review
Rogelio González-González, Sandra López-Verdín, Jesús Lavalle-Carrasco, Nelly Molina-Frechero, Mario Isiordia-Espinoza, Ramón G Carreón-Burciaga, Ronell Bologna-Molina
Rogelio González-González, Jesús Lavalle-Carrasco, Ramón G Carreón-Burciaga, Department of Research, School of Dentistry, Universidad Juárez del Estado de Durango, Durango 34000, Mexico
Sandra López-Verdín, Research Institute of Dentistry, Health Science Center, Universidad de Guadalajara, Guadalajara 4430, Mexico
Nelly Molina-Frechero, Department of Health Care, Xochimilco Unit, Universidad Autónoma Metropolitana Xochimilco, México 04960, Mexico
Mario Isiordia-Espinoza, Department of Clinics, Biomedical Sciences Division, Centro Universitario de los Altos, Universidad de Guadalajara, Tepetitlán de Morelos 47620, Mexico
Ronell Bologna-Molina, Molecular Pathology Area, School of Dentistry, Universidad de la República, Montevideo 11600, Uruguay
Author contributions: González-González R and Bologna-Molina R conceived and design the study, review the manuscripts selected, drafted and review the manuscript, López-Verdín S and Carreón-Burciaga RG made the bibliographic research, and review the manuscript, Lavalle-Carrasco J design the study, drafted and review the manuscript, Molina-Frechero N and Isiordia-Espinoza M made the bibliographic research and review the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
PRISMA 2009 Checklist statement: This study followed PRISMA guidelines in its performing, and PRISMA 2009 checklist was attached, this study does not evaluate biostatistical and different modalities treatments, only few targeted therapies reported cases.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ronell Bologna-Molina, DDS, MSc, PhD, Molecular Pathology Area, School of Dentistry, Universidad de la República, Las Heras 1925, Montevideo 11600, Uruguay.
ronellbologna@odon.edu.uy
Received: March 25, 2019
Peer-review started: March 26, 2019
First decision: September 2, 2019
Revised: October 23, 2019
Accepted: November 6, 2019
Article in press: November 6, 2019
Published online: January 24, 2020
Processing time: 278 Days and 3.6 Hours
ARTICLE HIGHLIGHTS
Research background
Ameloblastomas are benign tumors that arise from the odontogenic epithelium whose behavior is defined as aggressive, infiltrative, recurrent, with aesthetic implications and rarely propense to local and distant metastases. Recently B-raf proto-oncogene serine/threonine kinase (BRAF) V600E gene mutation has been reported in ameloblastomas. Thus, targeted therapies against this mutation have been evaluated as an alternative treatment. In this study, a systematic review was performed in order to evaluate the frequent mutation of BRAF and another associated mutations, as well as targeted therapies against them.
Research motivation
Performing a systematic review allows to know the reports of frequent mutations in ameloblastomas and alternative treatments against them, as well as evaluate therapeutic response.
Research objectives
The aim of this study was to evaluate the presence of BRAF V600E mutation and another related mutations in ameloblastomas and provide information about the role of the mutations in the behavior of ameloblastomas, as well as targeted therapies reported.
Research methods
A literature research was carried out between January 1st 2009-2019 in order to perform a systematic review, of which 19 articles with relevant content regarding BRAF and its mutations in ameloblastomas were included, as well as targeted therapies against them.
Research results
A total of 624 ameloblastomas were evaluated, in which BRAF V600E was the most frequent mutation. Of the total of the included articles, four case reports registered targeted therapies against BRAF V600E.
Research conclusion
In the current study, the most frequent mutation was BRAF V600E, which interestingly was frequently associated to other mutations that conferred more aggressiveness with recurrence and metastases. Regarding anatomic location, it is suggested that associated mutations to BRAF V600E are more common in the mandible. Targeted therapies against this mutation represented a significant outcome in patients that presented these types of tumors. Since this is the first systematic review developed about this subject, it could be suggested that the use of targeted therapies as adjuvant to surgical treatment may offer important outcome in the clinical evolution and the follow up, specially in recurrent, metastatic and malignant ameloblastic tumors.
Research prospective
The information obtained in this review demonstrates the current implementation of targeted therapies against BRAF V600E mutation in ameloblastic tumors.
